Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SANTA CLARA, Calif., Sept. 12, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the company’s CEO, Mike Kleine, was interviewed on Bloomberg Radio’s “Taking Stock” on September, 12th, 2016 at 3:15pm EDT.
In the interview, Mr. Kleine discussed the commercial momentum of the miraDry procedure and the significant market opportunity for the Company. The interview can be viewed at
http://www.bloomberg.com/news/audio/2016-09-12/miramar-labs-wipes-away-sweat-glands-and-odor-audio
“This interview with Bloomberg further demonstrates there is a growing interest in our company and the miraDry procedure. This is only one of the several steps we are taking to raise awareness and tell our story to current and potential investors, customers and patients,” commented Mr. Kleine.
About Miramar Labs
Miramar Labs, Inc., is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
Contacts: Investors: Brigid Makes Sr. Vice President & CFO 408-579-8700 [email protected] Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 [email protected] [email protected] Media/Other: Robert Ellis Vice President of Global Marketing Miramar Labs Phone: 408-579-8706 Email: [email protected] Chris Hippolyte The Ruth Group 646-536-7023 [email protected]
